Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

European approval granted for Sanofi-Synthelabo's Fasturtec

March 30, 2001

CPMP issues positive opinion for Fabrazyme

March 30, 2001

Dainippon's AR inhibitor improves diabetic neuropathy in laboratory study

March 30, 2001

NVP-DPP-728 improves glucose tolerance in rat model

March 30, 2001

Replagal receives positive opinion in E.U. for treatment of Fabry's disease

March 29, 2001

Abgenix and Diabetogen collaborate on development of anti-CD28 antibody therapy

March 29, 2001

P&G describes new PGF analogues particularly useful in bone disorders

March 28, 2001

Treatment with niacin may safely reduce cardiovascular risk factors in diabetic patients

March 28, 2001

Amylin and Alkermes initiate study of long-acting formulation of AC-2993

March 28, 2001

Pfizer to terminate agreement with Unigene for oral calcitonin

March 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...